2. Immunology/Inflammation
  3. Fc Receptor (FcR)
  4. Valziflocept

Valziflocept  (Synonyms: BAX1810; TAK-752; SM101)

Cat. No.: HY-P99529 Purity: 99.00%
COA
SDS
Technical Support

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE).

For research use only. We do not sell to patients.

CAS No. : 1804910-11-9

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Valziflocept Featured Recommendations:

Valziflocept Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE)[1][2][3].
In Vitro

Valziflocept (20 min incubation with opsonised MRBCs; 60 min co-culture with macrophages) significantly inhibits phagocytosis of IgG-opsonised murine red blood cells by thioglycolate-elicited peritoneal macrophages from female NZB/NZW F1 mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Valziflocept Related Antibodies
In Vivo

Valziflocept (200 μg per dose; i.v.; 5 occasions with 3-day intervals) significantly ameliorates collagen-induced arthritis in male DBA/1 mice, reducing mean arthritic scores, pathogenic antibody levels, and inflammatory cytokine mRNA expression[1].
Valziflocept (50-150 μg/week; s.c.; weekly; 4 weeks (prophylactic)) delays onset of lupus pathology and improves survival in NZB/NZW F1 mice, while valziflocept (100 μg/week; s.c.; weekly; until death or study end (therapeutic)) significantly prolongs survival despite established kidney damage[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DBA/1 (male, age-matched, collagen-induced arthritis model)[1]
Dosage: 200 μg per dose
Administration: i.v.; 5 occasions with 3-day intervals
Result: Reduced mean arthritic score to 6.1 at 12 days after first treatment and 14.2.
Reduced serum IgG anti-collagen type II antibody levels significantly 2 weeks after treatment start.
Reduced TNF-α and IL-6 mRNA levels significantly in lymph nodes.
Reduced TGF-β1, TGF-β2, TGF-β3, and MIF mRNA levels in synovial tissue.
Animal Model: NZB/NZW F1 (female, 5-8 weeks old at study start)[2]
Dosage: 150 μg/week (prophylactic, single weekly dose); 50 μg/week ×3 (prophylactic, three weekly doses); 100 μg/week (therapeutic, single weekly dose until death or study end)
Administration: s.c.; weekly; 4 weeks (prophylactic); s.c.; weekly; until death or study end (therapeutic)
Result: Significantly delayed onset of proteinuria with 3×50 μg/week prophylactic treatment.
Prolonged survival by 11.5 weeks with 3×50 μg/week prophylactic treatment.
Delayed weight loss and delayed development of anaemia with 3×50 μg/week prophylactic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 3×50 μg/week prophylactic treatment.
Showed a non-significant trend towards prolonged survival with 1×150 μg/week prophylactic treatment.
Significantly prolonged survival with 1×100 μg/week therapeutic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 1×100 μg/week therapeutic treatment.
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

19.693 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Valziflocept]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • FCGR2B (immunoglobulin G Fc receptor low affinity IIb, Fc gamma RIIb, CD32, CD32b)
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Valziflocept Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Valziflocept1804910-11-9BAX1810 TAK-752 SM101BAX 1810BAX-1810TAK752TAK 752TAK-752SM101SM 101SM-101Fc Receptor (FcR)Fc Receptormacrophagesinflammatory cytokinesmurine erythrocytesIgG anti-collagen type II antibodiesNZB/NZW F1 micemouse IgGFcγ receptorcollagen-induced arthritissystemic lupus erythematosusimmune complexesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Valziflocept
Cat. No.:
HY-P99529
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.